Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily glass of grapefruit juice shield aging hearts and bones?

NCT ID NCT01272167

Prevention Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This trial tests whether drinking grapefruit juice regularly over a long period can improve blood vessel function and bone health in healthy postmenopausal women. The study uses a crossover design, where each participant experiences both the juice and a control period, to isolate the specific role of a natural compound in grapefruit called naringin. The goal is to see if this everyday fruit juice could help prevent age-related conditions like cardiovascular disease and osteoporosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Long-term grapefruit juice consumption, with a focus on the flavanone naringin
What this could lead to
If grapefruit juice's flavanones prove protective, it could point toward a simple dietary approach to support heart and bone health in postmenopausal women.
What could go wrong
This is a small crossover study in a specific group, so results may not apply broadly. Grapefruit juice can interact with certain medications, and the effect on bone and vascular health remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

52 people

The number who actually took part.

Start date

Mar 2010

Finished

Dec 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Caucasian healthy post-menopausal women * 19≤ BMI ≤29 and waist measurement \> 88 cm Exclusion Criteria: * Metabolic diseases * Hypertension * Taking CYP3A4-metabolized drugs * Taking blood lipids lowering drugs or antihypertensive drugs * Hypercholesterolemia with HDL \< 1.30 mmol/L (i.e. \< 0.5 g/L) * Osteoporosis (defined by T-score of -2.5 SD at hip and/or lumbar spine) * Taking hormone replacement therapy (HRT) * Smokers * Taking dietary supplements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-menopausal status are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-menopausal status

Contacts and locations

Locations

  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.